Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.

home / news releases / eyepoint tumbles 30 premarket on failed phase 2 stud

EYPT - EyePoint tumbles 30% premarket on failed Phase 2 study

EyePoint Pharmaceuticals Inc.

2024-05-06 09:24:05 ET

EyePoint Pharmaceuticals ( NASDAQ: EYPT ) stock tumbled nearly 30% in premarket trading Monday after the company said a Phase 2 study for its eye drug Duravyu, also known as EYP-1901, failed to meet its primary endpoint in the treatment of non-proliferative diabetic retinopathy....

For further details see:

EyePoint tumbles 30% premarket on failed Phase 2 study
Stock Information
Company Name: EyePoint Pharmaceuticals Inc.
Stock Symbol: EYPT
Market: NASDAQ
Website: eyepointpharma.com
Menu
EYPT EYPT Quote EYPT Short EYPT News EYPT Articles EYPT Message Board
Get EYPT Alerts

News, Short Squeeze, Breakout and More Instantly...